SUMMIT, N.J.--(BUSINESS WIRE)-- 2007 Second Quarter Financial Results Year-Over-Year: * Total Revenue Increased 76 Percent To $348 Million * Product Sales Increased 81 Percent To $319 Million * REVLIMID® Net Product Sales Increased 187 Percent To $181 Million * THALOMID® Net Product Sales Totaled $118 Million * Adjusted Operating Income Increased 143 Percent To $130 Million * Adjusted Net Income Increased 160 Percent To $110 Million * Adjusted Earnings Per Share Increased 136 Percent To $0.26 Per Diluted Share
